ClinicalTrials.gg
RecruitingNCT06926868Updated Aug 10, 2026

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A Phase 2/3 interventional study of Iza-bren and Nab-paclitaxel in Breast Neoplasms, sponsored by Bristol-Myers Squibb. Recruiting at 295 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's title name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
29th of 605
600 · median 52
Started
2025
with 46 others
Phase 2/3
2 of 645
1 open now
Primary completion
2028-03
later than 178 of 263 live
Registered
581st of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 29th largest by planned enrollment of the 605 interventional ones that give a count, is one of 47 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 178 of the 263 other live ones, and was the 581st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • triple-negative breast cancer
  • antibody-drug conjugate
  • ER-low/HER2-negative breast cancer
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

This study's planned enrollment of 600 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed and documented locally-advanced, recurrent inoperable, or triple-negative breast cancer (TNBC) (ER \< 1%, PgR \< 1%, IHC 0, 1+, or 2+ with ISH negative for HER2 gene amplification) or ER-low, HER2-negative BC (ER and / or PgR 1% to 10%, HER2 IHC 0, 1+, or 2+ with ISH negative for HER2 gene amplification) per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, based on the most recently analyzed or other pathology specimen.
  • Patients with recurrent disease must have experienced disease relapse at least 6 months after finishing their last therapy with curative intent.
  • Participants with TNBC must be considered ineligible for 1L chemotherapy combination treatment with an (eg, pembrolizumab) or an anti-PD-L1 (eg, atezolizumab) due to any one of the following criteria:

    i) Investigator-determined ineligibility based on PD-L1 negative disease determined and documented prior to trial screening as part of standard of care (SoC); ii) Has experienced disease relapse between 6 to 12 months after the completion of (neo) therapy with an anti-PD(L)1; iii) Has a severe auto-immune disease or other , in the opinion of the investigator, for the use of an anti-PD(L)1 drug: iv) Any auto-immune disease that requires current (eg, methotrexate, cyclophosphamide, prednisone > 10 mg/day).

    v) Prior auto-immune AE to peri-adjuvant ICI that required immunosuppression. vi) Current Graves' disease with ophthalmopathy or in need of radioiodine or in use of antithyroid medication.

vii) Current or prior auto-immune diseases per below: A. Moderate to severe rheumatoid arthritis. B. Auto-immune hepatitis or cholangitis. C. Myasthenia gravis. D. Moderate-to-severe or poorly controlled inflammatory bowel disease. E. Multiple sclerosis. F. Lupus with kidney involvement or moderate to severe lupus. G. Auto-immune myocarditis. Note: if participant meets Inclusion Criteria 5b or 5c, unknown PDL1 results per local SOC are acceptable in these specific cases.

  • Patients with ER-low, HER2-negative BC must be ineligible, in the opinion of the Investigator, for endocrine therapy-based treatments.
  • No previous systemic therapy in the locally advanced, recurrent inoperable or metastatic setting (ie incurable setting).
  • by CT or MRI as per v1.1.

Exclusion criteria

Exclusion Criteria

  • Participants with a known germline breast cancer gene (BRCA) 1 or 2 mutation whose best 1L treatment option, in the opinion of the investigator, is a poli-ADP-ribose-polymerase inhibitors (PARPi).
  • Untreated symptomatic central nervous system (CNS) . Participants are eligible if have been treated, and participants' neurological signs and symptoms have returned to baseline. In addition, participants must have been either off , or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization. Imaging performed within 28 days of randomization must document radiographic stability of CNS lesions and be performed after completion of any CNS directed therapy.
  • .
  • Participants with history of severe heart disease including, but not limited to, any of the following:

    i) History of heart disease (eg, cardiomyopathy, congestive heart failure with functional classification II to IV, pericarditis, or significant pericardial effusion).

ii) Myocardial infarction, uncontrolled angina, or stroke/ within the past 6 months.

iii) (by Fridericia's formula) prolongation ≥ 450 msec for males and ≥ 470 msec for females, except for right bundle branch block.

iv) Known \< 50%.

  • Prior therapy with iza-bren or any other ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Arm A1

    Drug: Iza-bren

  • Experimental
    Arm A2

    Drug: Iza-bren

  • Active comparator
    Arm B

    Drug: Nab-paclitaxel · Drug: Paclitaxel · Drug: Capecitabine · Drug: Carboplatin · Drug: Gemcitabine

Interventions

  • Specified dose on specified days

    Also known as: BMS-986507, BL-B01D1, Izalontamab brengitecan

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

07

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  2. Recommended Phase 3 Dose (RP3D) of BMS-986507

    Time frame: Approximately 13 months from first participant randomization in Phase 2

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  2. Number of participants with treatment-related Adverse Events (AEs)

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  3. Number of participants with laboratory abnormalities

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  4. Number of participants with serious AEs (SAEs)

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  5. Number of participants with AEs leading to treatment discontinuation, interruption, dose reduction or dose delay

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  6. Number of deaths

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  7. Objective Response (OR) per BICR

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  8. Objective Response (OR) per Investigator

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  9. PFS rate

    Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by BICR

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  10. PFS rate

    Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by Investigator

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  11. Relative change in tumor size

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  12. Disease control rate (DCR) per BICR

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  13. Disease control rate (DCR) per Investigator

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  14. PFS

    Assessed by Investigator

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  15. Duration of Response (DOR) per BICR

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  16. Duration of response (DOR) per Investigator

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  17. Time to Response (TTR) per BICR

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  18. Time to response (TTR) per Investigator

    Time frame: Approximately 22 months from first participant randomization in Phase 3

  19. Time to subsequent treatment (TTST) per Investigator

    Defined as time from randomization to the start of subsequent therapy or death

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  20. Progression-free survival after next line of treatment (PFS2)

    Defined as the time from randomization to the date of investigator-defined documented disease progression after next line of treatment or death due to any cause, whichever comes first

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  21. Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  22. Change from baseline in EORTC Breast Cancer-specific Quality of Life Questionnaire (QLQ-BR23)

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  23. Functional Assessment of Chronic Illness Therapy item GP5 (FACIT GP5) score

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

  24. Change from baseline in European Quality of Life 5 Dimensions 5 Levels (EQ-5D-5L)

    Time frame: Approximately up to 47 months from first participant randomization in Phase 3

08

Study locations

168 of 295 sites recruiting
  • Local Institution - 0303
    Hot Springs, Arkansas 71913, United States
    Not yet recruiting
    • Site 0303 · Contact
  • Helios Clinical Research
    Cerritos, California 90703, United States
    Recruiting
    • Omkar Marathe, Site 0328 · Contact562-693-4477
  • Local Institution - 0307
    Cerritos, California 90703, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0308
    Cerritos, California 90703, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0309
    Cerritos, California 90703, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0311
    Long Beach, California 90805, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • Daphne Stewart, Site 0290 · Contact323-865-3906
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
    Recruiting
    • David Berz, Site 0283 · Contact424-535-1874
  • USC Norris Oncology/Hematology-Newport Beach
    Newport Beach, California 92663, United States
    Recruiting
    • Daphne Stewart, Site 0353 · Contact323-397-5954
  • Local Institution - 0358
    Stanford, California 94305, United States
    Not yet recruiting
    • Site 0358 · Contact
  • Local Institution - 0289
    Aurora, Colorado 80045, United States
    Not yet recruiting
    • Site 0289 · Contact
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80220, United States
    Recruiting
    • Mabel Mardones, Site 0367 · Contact
  • Medical Oncology Hematology Consultants, PA
    Newark, Delaware 19713, United States
    Recruiting
    • Jamal Misleh, Site 0304 · Contact302-366-1200
  • Local Institution - 0296
    Pembroke Pines, Florida 33028, United States
    Not yet recruiting
    • Site 0296 · Contact
  • Local Institution - 0294
    Atlanta, Georgia 30322, United States
    Completed

    Not enrolling at this site — choose another above.

  • Northside Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
    • Amelia Zelnak, Site 0357 · Contact770-205-5292
  • Local Institution - 0278
    Chicago, Illinois 60612, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0280
    Chicago, Illinois 60637, United States
    Not yet recruiting
    • Site 0280 · Contact
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
    Recruiting
    • James Wade, Site 0275 · Contact217-876-6611
  • Local Institution - 0324
    O'Fallon, Illinois 62269, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ochsner Clinic Foundation
    Covington, Louisiana 70433, United States
    Recruiting
    • Melanie Sheen, Site 0286 · Contact504-842-9780
  • Local Institution - 1035
    Baltimore, Maryland 21201, United States
    Not yet recruiting
    • Site 1035 · Contact
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Neelima Vidula, Site 0288 · Contact
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Sara Tolaney, Site 0287 · Contact617-632-5743
  • Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion)
    Detroit, Michigan 48202, United States
    Recruiting
    • Rebecca Chacko, Site 0359 · Contact313-530-1949
  • Minnesota Oncology Hematology
    Maple Grove, Minnesota 55369, United States
    Recruiting
    • Eric Lander, Site 0313 · Contact
  • Local Institution - 0372
    Minneapolis, Minnesota 55455, United States
    Not yet recruiting
    • Site 0372 · Contact
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
    Recruiting
    • Timothy Pluard, Site 0284 · Contact314-747-7992
  • Local Institution - 0312
    New York, New York 10016, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Nour Abuhadra, Site 0279 · Contact646-888-4451
  • Local Institution - 1037
    Syracuse, New York 13210, United States
    Not yet recruiting
    • Site 1037 · Contact
  • Clinical Research Alliance
    Westbury, New York 11590, United States
    Recruiting
    • Jonathan Goldberg, Site 0295 · Contact914-242-2991
  • White Plains Hospital
    White Plains, New York 10601, United States
    Recruiting
    • Dan Costin, Site 0285 · Contact914-849-7630
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
    Recruiting
    • Carey Anders, Site 0276 · Contact919-684-0313
  • Willamette Valley Cancer Institute
    Eugene, Oregon 97401, United States
    Recruiting
    • Miho Dougherty, Site 0316 · Contact
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18103, United States
    Recruiting
    • Nicholas Lamparella, Site 0356 · Contact610-402-9543
  • Abramson Cancer Center of The University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Payal Shah, Site 0310 · Contact
  • Local Institution - 0360
    Pittsburgh, Pennsylvania 15213-3403, United States
    Not yet recruiting
    • Site 0360 · Contact
  • St Francis Cancer Center
    Greenville, South Carolina 29607, United States
    Recruiting
    • Stephen Dyar, Site 0281 · Contact864-603-6327
  • Texas Oncology - Central/South Texas
    Austin, Texas 78705, United States
    Recruiting
    • Alvaro Restrepo, Site 0315 · Contact
  • Texas Oncology - West Texas
    El Paso, Texas 79902, United States
    Recruiting
    • Ines Sanchez-Rivera, Site 0368 · Contact915-544-6750
  • Texas Oncology - Northeast Texas
    Flower Mound, Texas 75028, United States
    Recruiting
    • Vibha Thomas, Site 0305 · Contact303-925-0700
  • (USOR) Texas Oncology
    Houston, Texas 77024-2843, United States
    Recruiting
    • Dhatri Kodali, Site 0314 · Contact555-555-5555
  • Bon Secours St. Francis Medical Center
    Midlothian, Virginia 23114, United States
    Recruiting
    • William Irvin, Site 0277 · Contact
  • Local Institution - 0301
    Roanoke, Virginia 24014, United States
    Not yet recruiting
    • Site 0301 · Contact
  • Shenandoah Oncology, P.C.
    Winchester, Virginia 22601, United States
    Recruiting
    • William Houck, Site 0302 · Contact540-662-1108
  • Local Institution - 0011
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1280, Argentina
    Not yet recruiting
    • Site 0011 · Contact
  • Hospital Italiano de Buenos Aires
    ABB, Buenos Aires F.D. 1181, Argentina
    Recruiting
    • Maria Riggi, Site 0214 · Contact5491165379382
  • Hospital Italiano de Córdoba
    Córdoba, Córdoba Province X5004BAL, Argentina
    Recruiting
    • Virginia Garcia, Site 0143 · Contact+5493515054293
  • Centro Privado de RMI Río Cuarto S.A. II
    Río Cuarto, Córdoba Province X5800ALB, Argentina
    Recruiting
    • Alejo Lingua, Site 0137 · Contact54351153819050
  • Sanatorio Plaza
    Rosario, Santa Fe Province 2000, Argentina
    Recruiting
    • Miriam Raimondo, Site 0142 · Contact+549341644-8821
  • Instituto Argentino de Diagnóstico y Tratamiento (IADT)
    Buenos Aires, 1122, Argentina
    Recruiting
    • Juan Cundom, Site 0345 · Contact(+54911)4162-5353
  • Centro Oncologico Korben
    Buenos Aires, 1426, Argentina
    Recruiting
    • Ernesto Korbenfeld, Site 0317 · Contact54911563819972
  • Instituto Alexander Fleming
    Buenos Aires, 1426, Argentina
    Recruiting
    • Adrian Nervo, Site 0012 · Contact+54932218900
  • Local Institution - 0346
    Buenos Aires, 1430, Argentina
    Not yet recruiting
    • Site 0346 · Contact
  • Fundación Oncológica Mendoza
    Mendoza, 5500, Argentina
    Recruiting
    • RUBEN RIZZO, Site 0348 · Contact+5492615109921
  • Macquarie University
    Macquarie University, New South Wales 2109, Australia
    Recruiting
    • Dhanusha Sabanathan, Site 0170 · Contact98122973
  • Royal Brisbane and Women's Hospital
    Brisbane, Queensland 4029, Australia
    Recruiting
    • Po-ling Inglis, Site 0035 · Contact61736468111
  • Grampians Health
    Ballarat Central, Victoria 3350, Australia
    Recruiting
    • LeeNa Teo, Site 0197 · Contact+61409338111
  • Austin Health
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • Belinda Yeo, Site 0031 · Contact0450737873
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
    Recruiting
    • Peter Savas, Site 0274 · Contact+61402147682
  • St. John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
    Recruiting
    • Daphne Tsoi, Site 0028 · Contact61864659200
  • Medizinische Universität Graz
    Graz, Styria 8036, Austria
    Recruiting
    • Vassiliki Kolovetsiou Kreiner, Site 0292 · Contact4331638580643
  • Medizinische Universitaet Innsbruck
    Innsbruck, Tyrol 6020, Austria
    Recruiting
    • Daniel Egle, Site 0268 · Contact004351250481503
  • Uniklinikum Salzburg
    Salzburg, 5020, Austria
    Recruiting
    • Simon Gampenrieder, Site 0267 · Contact435725558858
  • Universitätsklinikum St. Pölten
    Sankt Pölten, 3100, Austria
    Recruiting
    • Maria Gold, Site 0270 · Contact00432742900422175
  • Medizinische Universität Wien
    Vienna, 1090, Austria
    Recruiting
    • Rupert Bartsch, Site 0269 · Contact43140400444500
  • Local Institution - 0187
    Manaus, Amazonas 69020-030, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Oncocentro Oncologia
    Fortaleza, Ceará 60135-237, Brazil
    Recruiting
    • Roberto Furlani, Site 0147 · Contact+5585999211461
  • CEDOES
    Vitória, Espírito Santo 29055450, Brazil
    Recruiting
    • Mauricio Pereira, Site 0157 · Contact+5521998795727
  • Local Institution - 1038
    Lago Sul, Federal District 71681-603, Brazil
    Not yet recruiting
    • Site 1038 · Contact
  • Centro Integrado de Oncologia de Curitiba
    Curitiba, Paraná 81480-580, Brazil
    Recruiting
    • Karina Vianna, Site 0159 · Contact+554130242421
  • Futtura Oncology - Clinical Research Hub
    Porto Alegre, Rio Grande do Sul 90470-340, Brazil
    Recruiting
    • Gustavo Werutsky, Site 0199 · Contact51995868013
  • Fundação Pio XII - Hospital de Câncer de Barretos
    Barretos, São Paulo 14784400, Brazil
    Recruiting
    • Karina Oikawa, Site 0148 · Contact1733216600
  • Local Institution - 0164
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Not yet recruiting
    • Site 0164 · Contact
  • Instituto Nacional de Câncer - INCA
    Rio de Janeiro, 20230-130, Brazil
    Recruiting
    • Susanne Crocamo V Da Costa, Site 0153 · Contact552125774242
  • Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda
    São Paulo, 01317-000, Brazil
    Recruiting
    • Roberto Hegg, Site 0144 · Contact5511991931500
  • Instituto D'Or de Pesquisa e Ensino (IDOR)
    São Paulo, 01401-002, Brazil
    Recruiting
    • Renata Bonadio, Site 0149 · Contact+5511989554040
  • BC Cancer Kelowna
    Kelowna, British Columbia V1Y 5L3, Canada
    Recruiting
    • Susan Ellard, Site 0218 · Contact+1250-712-3996
  • Local Institution - 0217
    Victoria, British Columbia V8R 6V5, Canada
    Not yet recruiting
    • Site 0217 · Contact
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Xinni Song, Site 0265 · Contact6137377700ext70208
  • Centre Hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 3E4, Canada
    Recruiting
    • Danielle Charpentier, Site 0215 · Contact5148908000
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Jamil Asselah, Site 0219 · Contact514934193435721
  • Centre Intégré de Santé et de Services Sociaux de Lanaudière
    Saint-Charles-Borromée, Quebec J6E 6J2, Canada
    Recruiting
    • Angélique Brunot, Site 0350 · Contact579-593-1172
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUS
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
    • Michel Pavic, Site 0216 · Contact819-346-1110x74816
  • FALP
    Santiago, Santiago Metropolitan 7500921, Chile
    Recruiting
    • Felipe Reyes, Site 0138 · Contact56975798360
  • Clínica Alemana de Santiago
    Santiago, Santiago Metropolitan 7650568, Chile
    Recruiting
    • Jose Sola, Site 0021 · Contact+56994016361
  • Pontificia Universidad Catolica de Chile
    Santiago, Santiago Metropolitan 8330032, Chile
    Recruiting
    • Cesar Sanchez, Site 0017 · Contact56223546919
  • Bradfordhill
    Santiago, Santiago Metropolitan 8420383, Chile
    Recruiting
    • Carlos Gallardo, Site 0018 · Contact+56978878489
  • Oncocentro Apys
    Viña del Mar, Valparaiso 2520598, Chile
    Recruiting
    • Alejandro Acevedo Gaete, Site 0016 · Contact+56992369820
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
    Recruiting
    • Nannan Lu, Site 1002 · Contact8618130056850
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
    Recruiting
    • Fanfan Li, Site 1003 · Contact+8613855137365
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Huiping Li, Site 1005 · Contact8613811012595
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Donggui Wan, Site 1024 · Contact8619854715414
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, BEI 100021, China
    Recruiting
    • Binghe Xu, Site 1001 · Contact+86 13501028690
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350000, China
    Recruiting
    • Fan Wu, Site 1006 · Contact8613859082118
  • Fujian Medical University Union Hospital
    Fyzhou, Fujian 350001, China
    Recruiting
    • Fangmeng Fu, Site 1007 · Contact8613365917923
  • Local Institution - 1016
    Xiamen, Fujian 361003, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
    Recruiting
    • Xiaoling Ling, Site 1031 · Contact8618693165668
  • Guangxi Medical University Affiliated Cancer Hospital
    Nanning, Guangxi 530021, China
    Recruiting
    • Wei Wei, Site 1008 · Contact8618577071966

Showing the first 100 of 295 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Mar 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 15, 2025
StartActual
Sep 11, 2025
Primary completionEst.
Mar 13, 2028
CompletionEst.
May 15, 2030
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06926868
Collaborators
SystImmune Inc.
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Sep 11, 2025
Primary completion
Mar 13, 2028 (estimated)
Completion
May 15, 2030 (estimated)
Last update
Aug 10, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izalontamab brengitecan

Start the discussion